| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-115-9-687 |
| P698 | PubMed publication ID | 1929036 |
| P50 | author | William B. Kannel | Q15439387 |
| Peter Wilson | Q89854449 | ||
| P2093 | author name string | Wong ND | |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 687-693 | |
| P577 | publication date | 1991-11-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. | |
| P478 | volume | 115 |
| Q42879876 | A 50-Week Extension Study on the Safety and Efficacy of Colesevelam in Adults with Primary Hypercholesterolemia |
| Q93061441 | Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea |
| Q40482679 | An update on coronary risk factors |
| Q50866424 | Association of insulin resistance to electrocardiographic changes in non obese Asian Indian subjects with hypertension. |
| Q50099169 | Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study |
| Q34107382 | Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics |
| Q33702516 | Cardiovascular risk determination: discrepancy between total cholesterol evaluation and two compound laboratory indices in Norway |
| Q36863052 | Cholesterol and cardiovascular disease in the elderly. Facts and gaps |
| Q40368068 | Cholesterol in patients with coronary heart disease: how low should we go? |
| Q43832062 | Chromatic computerized analysis is an early predictor of cardiovascular risk associated to hypercholesterolemia |
| Q44234346 | Comparative study of the impact of diet versus pravastatin on color vision in Brodman area 19 detected by computerized chromatic analysis (CARDIOCOLOUR Study) |
| Q35137575 | Comparison of predictive value of cardiometabolic indices for subclinical atherosclerosis in Chinese adults |
| Q44328105 | Coronary artery disease--more disease, more patients, better treatment |
| Q51926489 | Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. |
| Q44657551 | Current Status of Lipid Management of Hypertensive Patients |
| Q33860933 | Current concepts in secondary prevention after acute myocardial infarction |
| Q60927628 | Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease |
| Q45335769 | Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group |
| Q41645991 | Dyslipidemia treatment guidelines and management systems in Kaiser Permanente |
| Q37195899 | Effect of Persistence with Drug Therapy On the Risk of Myocardial Re-infarction. |
| Q45264347 | Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial |
| Q34003468 | Evaluation of cardiovascular risk in blood donors: results of the CARDIORISK study in the Parma Transfusion Service |
| Q45182500 | How to read critically a prognostic cohort study |
| Q46007453 | Human genetics as a foundation for innovative drug development. |
| Q37855801 | Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins |
| Q30370672 | Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target |
| Q46210998 | Improvement in endothelium-dependent brachial artery flow-mediated vasodilation with low-density lipoprotein cholesterol levels <100 mg/dl |
| Q77958686 | Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events |
| Q34077942 | Is hypercholesterolemia a risk factor and should it be treated in the elderly? |
| Q34615583 | Lipid-lowering drug use and cardiovascular events after myocardial infarction |
| Q35232239 | Lipid-lowering therapy in older persons |
| Q35919279 | Lipids and the elderly |
| Q35166425 | Long-term prognostic importance of total cholesterol in elderly survivors of an acute myocardial infarction: the Cooperative Cardiovascular Pilot Project |
| Q26853114 | Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics |
| Q39443735 | Management of older persons after myocardial infarction |
| Q36445474 | Managing hyperlipidaemia in the elderly: special considerations for a population at high risk |
| Q35215088 | Managing the spectrum of dyslipidemia in primary care |
| Q35187308 | Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. |
| Q34725347 | Multiple cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group |
| Q44416953 | Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden |
| Q33653555 | Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study. |
| Q33645696 | Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease |
| Q37706943 | Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006. |
| Q48483930 | Prevalence of coronary artery disease, atherothrombotic brain infarction, and peripheral arterial disease: associated risk factors in older Hispanics in an academic hospital-based geriatrics practice |
| Q77714696 | Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention |
| Q40421165 | Range of serum cholesterol values in the population developing coronary artery disease |
| Q73456978 | Results of recent large cholesterol-lowering trials and implications for clinical management |
| Q44683749 | Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol |
| Q71063996 | Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease |
| Q77442995 | Risk factors for new coronary events in older African-American men and women |
| Q44110146 | Risk factors for new coronary events in older Hispanic men and women |
| Q34224601 | Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association |
| Q40503556 | Should high lipid levels in very old patients be lowered? |
| Q44125966 | Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated? |
| Q34146972 | The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link. |
| Q33741450 | The older man's heart and heart disease |
| Q60721365 | The relationship between aging and disease |
| Q37151940 | Treating to protect: current cardiovascular treatment approaches and remaining needs. |
| Q36993983 | Treatment after myocardial infarction |
| Q28191018 | Treatment of the elderly post-myocardial infarction patient |
| Q40421159 | Unresolved issues in early trials of cholesterol lowering |
| Q28485472 | Use of NHANES data to link chemical exposures to chronic diseases: a cautionary tale |
Search more.